|
ALL leukemic cells
|
7 μM
|
MTT assay
|
Download PDF
|
|
MCF10A-WT
|
1.488 µM
|
MTT assay; Absolute IC50 calculated using GraphPad PRISM 10.1.1, inhibitor vs. normalized response equation.
|
PMC12589559
|
|
MCF10A-T790M/+
|
0.3421 µM
|
MTT assay; Absolute IC50 calculated using GraphPad PRISM 10.1.1, inhibitor vs. normalized response equation.
|
PMC12589559
|
|
CLL leukemic cells
|
5 µM
|
MTT assay
|
Download PDF
|
|
Granta-519
|
14.35 µM
|
CellTiter 96 Cell Proliferation Assay, Calcusyn 2.0 software, GraphPad Prism 9
|
Download PDF
|
|
JeKo-1
|
0.56 µM
|
CellTiter 96 Cell Proliferation Assay, Calcusyn 2.0 software, GraphPad Prism 9
|
Download PDF
|
|
K562
|
0.85 µM
|
MTS assay
|
PMC10072273
|
|
RAJI
|
20.88 µM
|
MTS assay
|
PMC10072273
|
|
human primary fibroblasts
|
31.54 ± 1.22 µM
|
MTT metabolization method, nonlinear regression analysis
|
Download PDF
|
|
human primary keratinocytes
|
4.60 ± 1.56 µM
|
MTT metabolization method, nonlinear regression analysis
|
Download PDF
|
|
SKMEL-28 cells
|
8.22 ± 0.48 µM
|
MTT metabolization method, nonlinear regression analysis
|
Download PDF
|
|
HBL1
|
22.60 mmol/L
|
MTT assay
|
Download PDF
|
|
HBL1-IR
|
76.50 mmol/L
|
MTT assay
|
Download PDF
|
|
S180
|
77.98±5.76μM
|
MTT assay, plotting a graph of the log concentration of ibrutinib versus the percentage cell viability
|
Download PDF
|
|
BT474
|
0.09 µM
|
Resazurin assay to assess viability, GI50 values determined using Origin 6.0 software.
|
Download PDF
|
|
SKBR3
|
0.13 µM
|
Resazurin assay to assess viability, GI50 values determined using Origin 6.0 software.
|
Download PDF
|
|
AU565
|
0.31 µM
|
Resazurin assay to assess viability, GI50 values determined using Origin 6.0 software.
|
Download PDF
|
|
EFM192A
|
0.10 µM
|
Resazurin assay to assess viability, GI50 values determined using Origin 6.0 software.
|
Download PDF
|
|
JIMT1
|
> 5 µM
|
Resazurin assay to assess viability, GI50 values determined using Origin 6.0 software.
|
Download PDF
|
|
BT20
|
> 5 µM
|
Resazurin assay to assess viability, GI50 values determined using Origin 6.0 software.
|
Download PDF
|
|
HCC1806
|
> 5 µM
|
Resazurin assay to assess viability, GI50 values determined using Origin 6.0 software.
|
Download PDF
|
|
PMC42
|
> 5 µM
|
Resazurin assay to assess viability, GI50 values determined using Origin 6.0 software.
|
Download PDF
|
|
MCF7
|
> 5 µM
|
Resazurin assay to assess viability, GI50 values determined using Origin 6.0 software.
|
Download PDF
|
|
T47D
|
> 5 µM
|
Resazurin assay to assess viability, GI50 values determined using Origin 6.0 software.
|
Download PDF
|
|
Ri-1
|
0.514 μM
|
alamarBlue assay
|
PMC9213039
|
|
Ri-1
|
0.909 μM
|
alamarBlue assay
|
PMC9213039
|
|
SU-DHL-6
|
2.434 μM
|
Cell Counting Kit-8 (CCK-8) assay to detect cell viability by measuring optical density at 450 nm, IC50 calculated using GraphPad Prism 6 software.
|
PMC8798964
|
|
OCI-LY10
|
0.4671 μM
|
Cell Counting Kit-8 (CCK-8) assay to detect cell viability by measuring optical density at 450 nm, IC50 calculated using GraphPad Prism 6 software.
|
PMC8798964
|
|
BTK WT CLL patient cells
|
0.70 nM
|
BTK Y223 phosphorylation was normalized to total BTK and IC50 values were calculated using a 4-parameter fit in GraphPad Prism 9.3 software.
|
PMC10202739
|
|
HEK293 BTK WT
|
2.3 nM
|
BTK Y223 phosphorylation was normalized to total BTK in HEK293 BTK WT (B) and HEK293 BTK C481S (C) cells. IC50 values were calculated using a 4-parameter fit in GraphPad Prism software version 9.3.
|
PMC10202739
|
|
Ri-1
|
0.514 µM
|
proliferation assay
|
Download PDF
|
|
Raji
|
6.18 µM
|
proliferation assay
|
Download PDF
|
|
DLBCL cell lines
|
0.5 nM
|
selective toxicity assay, BTK autophosphorylation prevention
|
Download PDF
|
|
human peripheral blood mononuclear cells
|
<10 nM
|
cellular assays
|
Download PDF
|
|
DaudiB
|
2.78 ± 1.31 μM
|
Cell Counting Kit-8 reagent
|
Download PDF
|
|
A20
|
35.51 ± 1.06 μM
|
Cell Counting Kit-8 reagent
|
Download PDF
|
|
B16
|
45.95 ± 1.04 μM
|
Cell Counting Kit-8 reagent
|
Download PDF
|
|
A375
|
25.85 ± 1.07 μM
|
Cell Counting Kit-8 reagent
|
Download PDF
|
|
MCF-10A
|
22.98 ± 1.32 μM
|
Cell Counting Kit-8 reagent
|
Download PDF
|
|
DU145
|
32µM
|
MTT assay
|
PMC7231774
|
|
DU145
|
21µM
|
MTT assay
|
PMC7231774
|
|
DU145
|
16µM
|
MTT assay
|
PMC7231774
|
|
PC3
|
53µM
|
MTT assay
|
PMC7231774
|
|
PC3
|
34µM
|
MTT assay
|
PMC7231774
|
|
PC3
|
22µM
|
MTT assay
|
PMC7231774
|
|
PANC-1
|
20.8 μmol/L
|
Cell Counting Kit-8 (CCK-8) assay
|
Download PDF
|
|
Capan2
|
29.6 μmol/L
|
Cell Counting Kit-8 (CCK-8) assay
|
Download PDF
|
|
MEC1
|
0.99 µM
|
MTS cell viability assays, calculated by fitting variable slope non-linear curves to normalised response data from drug treatments using GraphPad Prism v5.
|
Download PDF
|
|
MEC1
|
4.13 µM
|
MTS cell viability assays, calculated by fitting variable slope non-linear curves to normalised response data from drug treatments using GraphPad Prism v5.
|
Download PDF
|
|
JVM2
|
3.64 µM
|
MTS cell viability assays, calculated by fitting variable slope non-linear curves to normalised response data from drug treatments using GraphPad Prism v5.
|
Download PDF
|
|
JVM2
|
8.95 µM
|
MTS cell viability assays, calculated by fitting variable slope non-linear curves to normalised response data from drug treatments using GraphPad Prism v5.
|
Download PDF
|
|
RCH-ACV
|
2.8 μM
|
MTT assay
|
PMC7306596
|
|
RCH-ACV
|
1.16 μM
|
MTT assay
|
PMC7306596
|
|
OCI-Ly7
|
6.60 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
SU-DHL-2
|
18.38 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
SU-DHL-6
|
1.83 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
SU-DHL-16
|
6.31 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
Pfeiffer
|
0.014 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
OCI-Ly3
|
26.82 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
WSU-NHL
|
2.32 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
RL
|
6.18 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
DOHH-2
|
0.52 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
JVM3
|
18.67 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
Mino
|
6.62 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
JVM2
|
28.68 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
JVM13
|
16.73 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
Jeko-1
|
20.43 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
Granta519
|
21.12 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
Z138
|
19.24 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
Namalwa
|
>50 μM
|
Cell Titer-Glo luminescent cell viability assay
|
Download PDF
|
|
32D (WT G-CSFR)
|
250 nM
|
Trypan Blue based live/dead cell counting
|
PMC6320735
|
|
32D (mutant G-CSFR)
|
50 nM
|
Trypan Blue based live/dead cell counting
|
PMC6320735
|
|
c-Kit+ bone marrow cells (WT)
|
129 nM
|
Cell viability/proliferation assay (Trypan Blue based live/dead cell counting)
|
PMC6320735
|
|
c-Kit+ bone marrow cells (Q741x mutant)
|
32 nM
|
Cell viability/proliferation assay (Trypan Blue based live/dead cell counting)
|
PMC6320735
|
|
EHEB
|
18 μM
|
Cell viability examined by Trypan blue dye exclusion and MTT assay; IC50 values calculated from dose-response curves by plotting cell survival (%) versus drug concentration.
|
Download PDF
|
|
EHEB
|
11.5 μM
|
Cell viability examined by Trypan blue dye exclusion and MTT assay; IC50 values calculated from dose-response curves by plotting cell survival (%) versus drug concentration.
|
Download PDF
|
|
JVM-2
|
14.8 μM
|
Cell viability examined by Trypan blue dye exclusion and MTT assay; IC50 values calculated from dose-response curves by plotting cell survival (%) versus drug concentration.
|
Download PDF
|
|
JVM-2
|
5.4 μM
|
Cell viability examined by Trypan blue dye exclusion and MTT assay; IC50 values calculated from dose-response curves by plotting cell survival (%) versus drug concentration.
|
Download PDF
|
|
JVM-3
|
19 μM
|
Cell viability examined by Trypan blue dye exclusion and MTT assay; IC50 values calculated from dose-response curves by plotting cell survival (%) versus drug concentration.
|
Download PDF
|
|
JVM-3
|
14.8 μM
|
Cell viability examined by Trypan blue dye exclusion and MTT assay; IC50 values calculated from dose-response curves by plotting cell survival (%) versus drug concentration.
|
Download PDF
|
|
MEC-1
|
18.6 μM
|
Cell viability examined by Trypan blue dye exclusion and MTT assay; IC50 values calculated from dose-response curves by plotting cell survival (%) versus drug concentration.
|
Download PDF
|
|
MEC-1
|
10 μM
|
Cell viability examined by Trypan blue dye exclusion and MTT assay; IC50 values calculated from dose-response curves by plotting cell survival (%) versus drug concentration.
|
Download PDF
|
|
MEC-2
|
15.3 μM
|
Cell viability examined by Trypan blue dye exclusion and MTT assay; IC50 values calculated from dose-response curves by plotting cell survival (%) versus drug concentration.
|
Download PDF
|
|
MEC-2
|
10 μM
|
Cell viability examined by Trypan blue dye exclusion and MTT assay; IC50 values calculated from dose-response curves by plotting cell survival (%) versus drug concentration.
|
Download PDF
|
|
SU-DHL-16
|
2.027 μM
|
Cell Titer-Glo Luminescent Cell Viability Assay
|
Download PDF
|
|
OCI-Ly7
|
8.293 μM
|
Cell Titer-Glo Luminescent Cell Viability Assay
|
Download PDF
|
|
FAM213A (recombinant protein)
|
1.0 μM
|
Gel-based ABPP
|
PMC4138289
|
|
MLTK (recombinant protein)
|
0.7 μM
|
Gel-based ABPP
|
PMC4138289
|
|
BTK (in Ramos cells)
|
2 nM
|
Competitive ABPP
|
PMC4138289
|
|
B-NHL cell lines (panel)
|
> 10 μM
|
MTT assay
|
Download PDF
|
|
Z-138
|
152.4 μM
|
MTT assay
|
Download PDF
|
|
GRANTA-519
|
22.1 μM
|
MTT assay
|
Download PDF
|
|
JVM-2
|
77.4 μM
|
MTT assay
|
Download PDF
|
|
UPN-1
|
2.4 μM
|
Dose-response curve
|
Download PDF
|
|
UPN-IbruR
|
24.6 μM
|
Dose-response curve
|
Download PDF
|
|
Human Basophils (healthy donors, allergic patients)
|
0.01 +/- 0.01 lmol/L
|
Histamine release assay
|
Download PDF
|
|
Human Basophils (normal, allergic patients)
|
0.1-0.5 lmol/L
|
Flow cytometry (MFI analysis)
|
Download PDF
|
|
HMC-1.1
|
4.45 lmol/L
|
3H-thymidine uptake
|
Download PDF
|
|
HMC-1.2
|
9.04 lmol/L
|
3H-thymidine uptake
|
Download PDF
|
|
KU812
|
2.98 lmol/L
|
3H-thymidine uptake
|
Download PDF
|
